Memantine
- TRADE NAMES: Akatinol; Ebixa (Lundbeck); Namenda (Forest)
- INDICATIONS: Alzheimer's disease, vascular dementia
- CLASS: Adamantane, NMDA receptor antagonist
- HALF-LIFE: 60–80 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amantadine, Bromocriptine, Darifenacin, Dextromethorphan, Ketamine, Levodopa, Levomepromazine, Oxybutynin, Risperidone, Rotigotine, Tiotropium, Trimethoprim, Trospium, Zuclopenthixol
PREGNANCY CATEGORY: B
Please login to see the rest of this drug profile
SKIN.
HAIR.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of memantine in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
